NanoViricides Emphasizes Importance of NV-387
NanoViricides emphasizes "the critical need for a revolutionary, broad-spectrum, antiviral drug like NV-387" in light of the recent Andes hantavirus incident on a cruise ship that has led to a flurry of worldwide activity to effectively quarantine the ship MV Hondius and trace passengers' contacts in an effort to prevent a potential global epidemic. "NV-387 could have possibly saved lives of the infected patients, given the preponderance of evidence on effectiveness of NV-387 in lethal lung infections in animal models," said Anil Diwan, CEO, adding, "Physicians in charge could have sought it under emergency or expanded use procedures, given that there is no drug for the treatment of hantavirus infections. NV-387 has successfully completed Phase I clinical trial of safety and tolerability in healthy human volunteers." The Andes hantavirus infects directly into the lungs via fomites from infected persons. The company said, "NanoViricides, Inc. has used exactly this route of infection in our lethal animal models of many distinctly different viruses for testing NV-387. We have found NV-387 to be highly effective in treating every one of the viruses that we have tried so far, including: Coronaviruses, RSV, Influenza, Monkeypox, and even Measles virus."
